New hope for aggressive blood cancer: adding a targeted drug to standard chemo
NCT ID NCT02310321
Summary
This study tested whether adding a new targeted drug called gilteritinib to standard chemotherapy was safe and effective for people newly diagnosed with acute myeloid leukemia (AML), a fast-growing blood cancer. The first part of the study aimed to find the safest dose. The second part focused on patients with a specific genetic change (FLT3 mutation) to see if the combination helped them achieve remission. The goal was to better control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SIte JP81011
Ōmura, Nagasaki, Japan
-
Site JP00001
Fukuoka, Japan
-
Site JP00002
Maebashi, Gunma, Japan
-
Site JP00003
Nagoya, Aichi-ken, Japan
-
Site JP00005
Shinagawa-ku, Tokyo, Japan
-
Site JP00006
Yokohama, Kanagawa, Japan
-
Site JP00007
Kobe, Hyōgo, Japan
-
Site JP81001
Maebashi, Gunma, Japan
-
Site JP81003
Nagoya, Aichi-ken, Japan
-
Site JP81004
Fukuoka, Japan
-
Site JP81005
Yokohama, Kanagawa, Japan
-
Site JP81006
Kobe, Hyōgo, Japan
-
Site JP81007
Yoshida-gun, Fukui, Japan
-
Site JP81008
Chiba, Japan
-
Site JP81009
Okayama, Japan
-
Site JP81010
Narita, Chiba, Japan
-
Site JP81012
Nagasaki, Japan
-
Site JP81013
Isehara, Kanagawa, Japan
-
Site JP81014
Sapporo, Hokkaido, Japan
-
Site JP81015
Sapporo, Hokkaido, Japan
-
Site JP81016
Kyoto, Japan
-
Site JP81018
Ōtake, Hiroshima, Japan
-
Site JP81019
Osaka, Japan
-
Site JP81020
Kanazawa, Ishikawa-ken, Japan
-
Site JP81021
Osaka, Japan
-
Site JP81022
Shimono, Tochigi, Japan
-
Site JP81023
Tsukuba, Ibaraki, Japan
-
Site JP81024
Yokohama, Kanagawa, Japan
-
Site JP81025
Fukuoka, Japan
-
Site JP81026
Fukuyama, Hiroshima, Japan
-
Site JP81027
Nagoya, Aichi-ken, Japan
-
Site JP81028
Kumamoto, Japan
-
Site JP81029
Akita, Japan
-
Site JP81030
Gifu, Japan
-
Site JP81031
Fukushima, Japan
-
Site JP81032
Shinagawa-ku, Tokyo, Japan
-
Site JP81033
Kochi, Japan
-
Site JP81035
Sendai, Miyagi, Japan
-
Site JP81036
Mito, Ibaraki, Japan
-
Site JP81037
Anjo, Aichi-ken, Japan
-
Site JP81038
Toyohashi, Aichi-ken, Japan
-
Site JP81039
Matsuyama, Ehime, Japan
-
Site JP81040
Bunkyo-ku, Tokyo, Japan
-
Site JP81041
Tenri, Nara, Japan
-
Site JP81043
Himeji, Hyōgo, Japan
-
Site KR82001
Seoul, South Korea
-
Site KR82002
Incheon, South Korea
-
Site KR82003
Seoul, South Korea
-
Site KR82004
Seoul, South Korea
-
Site KR82005
Busan, South Korea
-
Site KR82006
Seoul, South Korea
-
Site TW88601
Tainan, Taiwan
-
Site TW88602
Taichung, Taiwan
-
Site TW88603
Taoyuan District, Taiwan
-
Site TW88604
Kaohsiung City, Taiwan
Conditions
Explore the condition pages connected to this study.